---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-114773"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:47:02.375375+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TransCode gets Nasdaq extension to regain compliance; Public Reprimand issued

## Summary
- Nasdaq Hearings Panel granted extension to comply with Bid Price Rule 5550(a)(2), Equity Rule 5550(b), and Shareholder Approval Rule 5635(d).
- Company issued 10M shares at $0.30 on July 22, 2024, a 62% discount to the $0.7925 minimum price, without shareholder approval.
- Panel issued a Public Reprimand Letter for the unauthorized issuance; company remains listed subject to conditions.
- TransCode must demonstrate compliance with listing rules within the extension period or face delisting.

## SEC filing metadata
- accession: 0001104659-24-114773
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924114773/0001104659-24-114773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924114773/tm2427567d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-114773
- JSON: https://secwatch.observer/filing/0001104659-24-114773.json
- Plain text: https://secwatch.observer/filing/0001104659-24-114773.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.